microRNA在原发性胆汁性胆管炎发病机制、诊断和疗效评估中的作用

王静; 张碧擎; 潘韵芝; 朱传武

doi:10.3969/j.issn.1001-5256.2019.07.047

microRNA在原发性胆汁性胆管炎发病机制、诊断和疗效评估中的作用

DOI: 10.3969/j.issn.1001-5256.2019.07.047

苏州大学附属第三医院 a.感染性疾病科; b.中医科
苏州市第五人民医院

详细信息

中图分类号: R575.7
计量
- 文章访问数: 358
- HTML全文浏览量: 13
- PDF下载量: 118
- 被引次数: 0
出版历程
- 收稿日期: 2019-01-08
- 出版日期: 2019-07-20

Role of microRNA in the pathogenesis, diagnosis, and outcome evaluation of primary biliary cholangitis

Department of Infectious Diseases, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu 213003, China

摘要

摘要:
原发性胆汁性胆管炎(PBC)是一种常见的自身免疫性肝病之一,目前其发病机制仍不明确。归纳了microRNA在PBC发病机制及诊断、疗效评估中的作用,提示microRNA可能参与PBC的发生与发展过程,并可作为诊断和评估疗效的潜在生物标志物。
- 微RNAs /
- 原发性胆汁性胆管炎 /
- 病理过程 /
- 诊断 /
- 治疗学
Abstract:
Primary biliary cholangitis ( PBC) is one of common autoimmune liver diseases, and its pathogenesis remains unclear. This article summarizes the role of microRNA in the pathogenesis, diagnosis, and outcome evaluation of PBC and points out that microRNA may be involved in the development and progression of PBC and may thus be used as a potential biomarker for diagnosis and outcome evaluation.
- microRNAs /
- primary biliary cholangitis /
- pathologic processes /
- diagnosis /
- therapeutics

HTML全文

参考文献(45)

[1]CAREY EJ, ALI AH, LINDOR KD.Primary biliary cirrhosis[J].Lancet, 2015, 386 (10003) :1565-1575.

[2]SELMI C, BOWLUS CL, GERSHWIN ME, et al.Primary biliary cirrhosis[J].Lancet, 2011, 377 (9777) :1600-1609.

[3]GULAMHUSEIN AF, HIRSCHFIELD GM.Pathophysiology of primary biliary cholangitis[J].Best Pract Res Clin Gastroenterol, 2018, 34-35:17-25.

[4]TANAKA A, LEUNG PSC, GERSHWIN ME.The genetics and epigenetics of primary biliary cholangitis[J].Clin Liver Dis, 2018, 22 (3) :443-455.

[5]GULAMHUSEIN AF, LAZARIDIS KN.Primary biliary cholangitis, DNA, and beyond:The Relative contribution of genes[J].Hepatology, 2018, 68 (1) :19-21.

[6]RODRIGUES PM, PERUGORRIA MJ, SANTOS-LASO A, et al.Primary biliary cholangitis:A tale of epigenetically-induced secretory failure?[J].J Hepatol, 2018, 69 (6) :1371-1383.

[7]WANG L, HAN Y.An excerpt of primary biliary cholangitis:2018 practice guidance from the American Association for the Study of Liver Diseases[J].J Clin Hepatol, 2018, 34 (11) :2300-2304. (in Chinese) 王璐, 韩英.《2018年美国肝病学会原发性胆汁性胆管炎实践指导》摘译[J].临床肝胆病杂志, 2018, 34 (11) :2300-2304.

[8]WANG QX, MA X.Primary biliary cholangitis:Opportunities and challenges[J].J Clin Hepatol, 2017, 33 (11) :2049-2051. (in Chinese) 王绮夏, 马雄.原发性胆汁性胆管炎:机遇与挑战[J].临床肝胆病杂志, 2017, 33 (11) :2049-2051.

[9]OLAIZOLA P, LEE-LAW PY, ARBELAIZ A, et al.MicroRNAs and extracellular vesicles in cholangiopathies[J].Biochim Biophys Acta Mol Basis Dis, 2018, 1864 (4 Pt B) :1293-1307.

[10]DYSON JK, HIRSCHFIELD GM, ADAMS DH, et al.Novel therapeutic targets in primary biliary cirrhosis[J].Nat Rev Gastroenterol Hepatol, 2015, 12 (3) :147-158.

[11]PARES A, CABALLERIA L, RODES J.Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic Acid[J].Gastroenterology, 2006, 130 (3) :715-720.

[12]HIRSCHFIELD GM, MASON A, LUKETIC V, et al.Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid[J].Gastroenterology, 2015, 148 (4) :751-761, e8.

[13]SZABO G, BALA S.MicroRNAs in liver disease[J].Nat Rev Gastroenterol Hepatol, 2013, 10 (9) :542-552.

[14]ESPARZA-BAQUER A, LABIANO I, BUJANDA L, et al.MicroRNAs in cholangiopathies:Potential diagnostic and therapeutic tools[J].Clin Res Hepatol Gastroenterol, 2016, 40 (1) :15-27.

[15]TAN Y, PAN T, YE Y, et al.Serum microRNAs as potential biomarkers of primary biliary cirrhosis[J].PLo S One, 2014, 9 (10) :e111424.

[16]PADGETT KA, LAN RY, LEUNG PC, et al.Primary biliary cirrhosis is associated with altered hepatic microRNA expression[J].J Autoimmun, 2009, 32 (3-4) :246-253.

[17]QIN B, HUANG F, LIANG Y, et al.Analysis of altered microR-NA expression profiles in peripheral blood mononuclear cells from patients with primary biliary cirrhosis[J].J Gastroenterol Hepatol, 2013, 28 (3) :543-550.

[18]BANALES JM, SAEZ E, URIZ M, et al.Up-regulation of microRNA 506 leads to decreased Cl-/HCO3-anion exchanger2 expression in biliary epithelium of patients with primary biliary cirrhosis[J].Hepatology, 2012, 56 (2) :687-697.

[19]XIE YQ, MA HD, LIAN ZX.Epigenetics and Primary Biliary Cirrhosis:A comprehensive review and implications for autoimmunity[J].Clin Rev Al ergy Immunol, 2016, 50 (3) :390-403.

[20]ERICE O, MUNOZ-GARRIDO P, VAQUERO J, et al.MicroRNA-506 promotes primary biliary cholangitis-like features in cholangiocytes and immune activation[J].Hepatology, 2018, 67 (4) :1420-1440.

[21]ANANTHANARAYANAN M, BANALES JM, GUERRA MT, et al.Post-translational regulation of the type III inositol 1, 4, 5-trisphosphate receptor by miRNA-506[J].J Biol Chem, 2015, 290 (1) :184-196.

[22]KATSUMI T, NINOMIYA M, NISHINA T, et al.MiR-139-5p is associated with inflammatory regulation through c-FOSsuppression, and contributes to the progression of primary biliary cholangitis[J].Lab Invest, 2016, 96 (11) :1165-1177.

[23]KEMPINSKA-PODHORODECKA A, MILKIEWICZ M, WASIK U, et al.Decreased expression of vitamin D receptor affects an immune response in primary biliary cholangitis via the VDR-miR-NA155-SOCS1 pathway[J].Int J Mol Sci, 2017, 18 (2) :E289.

[24]WASIK U, MILKIEWICZ M, KEMPINSKA-PODHORODECKAA, et al.Protection against oxidative stress mediated by the Nrf2/Keap1 axis is impaired in primary biliary cholangitis[J].Sci Rep, 2017, 7:44769.

[25]WANG X, WEN X, ZHOU J, et al.MicroRNA-223 and microRNA-21 in peripheral blood B cells associated with progression of primary biliary cholangitis patients[J].PLo S One, 2017, 12 (9) :e0184292.

[26]NAKAGAWA R, MUROYAMA R, SAEKI C, et al.miR-425regulates inflammatory cytokine production in CD4 (+) T cells via N-Ras upregulation in primary biliary cholangitis[J].JHepatol, 2017, 66 (6) :1223-1230.

[27] QIAN Z, CHEN SX, REN CL, et al.Abnormal expression of miR-let-7b in primary biliary cirrhosis and its clinical significance[J].Chin J Hepatol, 2013, 21 (7) :533-536. (in Chinese) 钱琤, 陈孙孝, 任传路, 等.原发性胆汁性肝硬化患者miR-let-7b的异常表达及其意义[J].中华肝脏病杂志, 2013, 21 (7) :533-536.

[28]KATSUSHIMA F, TAKAHASHI A, SAKAMOTO N, et al.Expression of micro-RNAs in peripheral blood mononuclear cells from primary biliary cirrhosis patients[J].Hepatol Res, 2014, 44 (10) :e189-e197.

[29]TOMIYAMA T, YANG G X, ZHAO M, et al.The modulation of costimulatory molecules by circulating exosomes in primary biliary cirrhosis[J].Cell Mol Immunol, 2017, 14 (3) :276-284.

[30]LIANG DY, HOU YQ, LUO LJ, et al.Altered expression of miR-92a correlates with Th17 cell frequency in patients with primary biliary cirrhosis[J].Int J Mol Med, 2016, 38 (1) :131-138.

[31]YAMAURA Y, TATSUMI N, TAKAGI S, et al.Serum microRNAprofiles in patients with chronic hepatitis B, chronic hepatitis C, primary biliary cirrhosis, autoimmune hepatitis, nonalcoholic steatohepatitis, or drug-induced liver injury[J].Clin Biochem, 2017, 50 (18) :1034-1039.

[32]SAKAMOTO T, MORISHITA A, NOMURA T, et al.Identification of microRNA profiles associated with refractory primary biliary cirrhosis[J].Mol Med Rep, 2016, 14 (4) :3350-3356.

[33]NINOMIYA M, KONDO Y, FUNAYAMA R, et al.Distinct microRNAs expression profile in primary biliary cirrhosis and evaluation of miR 505-3p and miR197-3p as novel biomarkers[J].PLo S One, 2013, 8 (6) :e66086.

[34]AIBA Y, NAKAMURA M, JOSHITA S, et al.Genetic polymorphisms in CTLA4 and SLC4A2 are differentially associated with the pathogenesis of primary biliary cirrhosis in Japanese patients[J].J Gastroenterol, 2011, 46 (10) :1203-1212.

[35]SALAS JT, BANALES JM, SARVIDE S, et al.Ae2a, b-deficient mice develop antimitochondrial antibodies and other features resembling primary biliary cirrhosis[J].Gastroenterology, 2008, 134 (5) :1482-1493.

[36]MINAGAWA N, NAGATA J, SHIBAO K, et al.Cyclic AMP regulates bicarbonate secretion in cholangiocytes through release of ATP into bile[J].Gastroenterology, 2007, 133 (5) :1592-1602.

[37]SHIBAO K, HIRATA K, ROBERT ME, et al.Loss of inositol 1, 4, 5-trisphosphate receptors from bile duct epithelia is a common event in cholestasis[J].Gastroenterology, 2003, 125 (4) :1175-1187.

[38]YE D, ZHANG T, LOU G, et al.Role of miR-223 in the pathophysiology of liver diseases[J].Exp Mol Med, 2018, 50 (9) :128.

[39]AFONSO MB, RODRIGUES PM, SIMAO AL, et al.miRNA-21 ablation protects against liver injury and necroptosis in cholestasis[J].Cell Death Differ, 2018, 25 (5) :857-872.

[40]KAMEL RR, AMR KS, AFIFY M, et al.Relation between microRNAs and apoptosis in hepatocellular carcinoma[J].Open Access Maced J Med Sci, 2016, 4 (1) :31-37.

[41]FIORINO S, BACCHI-REGGIANI ML, VISANI M, et al.MicroRNAs as possible biomarkers for diagnosis and prognosis of hepatitis B-and C-related-hepatocellular-carcinoma[J].World J Gastroenterol, 2016, 22 (15) :3907-3936.

[42]GATSELIS NK, DALEKOS GN.Molecular diagnostic testing for primary biliary cholangitis[J].Expert Rev Mol Diagn, 2016, 16 (9) :1001-1010.

[43]MCDANIEL K, HALL C, SATO K, et al.Lin28 and let-7:Roles and regulation in liver diseases[J].Am J Physiol Gastrointest Liver Physiol, 2016, 310 (10) :g757-g765.

[44]SATO K, MENG F, GLASER S, et al.Exosomes in liver pathology[J].J Hepatol, 2016, 65 (1) :213-221.

[45]QIN LX, SUN HT, WANG CQ.Application of the exosome in diagnosis and treatment of digestive system cancers[J].Chin J Dig Surg, 2018, 17 (4) :333-337. (in Chinese) 钦伦秀, 孙豪庭, 王超群.外泌体在消化系统肿瘤精准诊断与治疗中的应用[J].中华消化外科杂志, 2018, 17 (4) :333-337.

施引文献

资源附件(0)

访问统计